Abstract: Disclosed herein are compositions including reagents for detecting human autoantibodies against at least two proteins selected from the group consisting of A1AT, ANGPTL4, LRP10, GFRA1, LGALS3, CST2, DKK1, CAPC, GRP78, and GRN, wherein at least one of the antibody detection markers is selected from the group consisting of A1AT, LGALS3, and CAPC, and their use in monitoring efficacy of breast cancer therapy and breast cancer recurrence.

Abstract: This invention relates to a method for detecting the presence of or likelihood of a patient of developing occult pancreatic beta cell dysfunction, and a method for detecting the presence of or likelihood of a patient of developing clinically significant post-prandial hyperglycemia. The methods involve (a) measuring a level of alpha-hydroxybutyrate (AHB) in a single fasting baseline biological sample of the patient; (b) comparing the level of AHB in the single fasting baseline biological sample to a reference AHB level; and (c) determining the presence of or likelihood of developing the disorder in the patient based on the comparison in step (b). An increased AHB level at fasting baseline indicates that a normoglycemic, normo-insulinemic and/or non-dyslipidemic patient has developed or has an increased likelihood of developing occult pancreatic beta cell dysfunction.

Abstract: This invention relates to a method for detecting the presence of or likelihood of a patient of developing occult pancreatic beta cell dysfunction, and a method for detecting the presence of or likelihood of a patient of developing clinically significant post-prandial hyperglycemia. The methods involve (a) measuring a level of alpha-hydroxybutyrate (AHB) in a single fasting baseline biological sample of the patient; (b) comparing the level of AHB in the single fasting baseline biological sample to a reference AHB level; and (c) determining the presence of or likelihood of developing the disorder in the patient based on the comparison in step (b). An increased AHB level at fasting baseline indicates that a normoglycemic, normo-insulinemic and/or non-dyslipidemic patient has developed or has an increased likelihood of developing occult pancreatic beta cell dysfunction.

Abstract: Disclosed herein are compositions including reagents for detecting human autoantibodies against at least two proteins selected from the group consisting of A1AT, ANGPTL4, LRPIO, GFRA1, LGALS3, CST2, DKK1, CAPC, GRP78, and GRN, wherein at least one of the antibody detection markers is selected from the group consisting of A 1 AT, LGALS3, and CAPC, and their use in monitoring efficacy of breast cancer therapy and breast cancer recurrence.

Abstract: This invention relates to a method for detecting the presence of or likelihood of a patient of developing occult pancreatic beta cell dysfunction, and a method for detecting the presence of or likelihood of a patient of developing clinically significant post-prandial hyperglycemia. The methods involve (a) measuring a level of alpha-hydroxybutyrate (AHB) in a single fasting baseline biological sample of the patient; (b) comparing the level of AHB in the single fasting baseline biological sample to a reference AHB level; and (c) determining the presence of or likelihood of developing the disorder in the patient based on the comparison in step (b). An increased AHB level at fasting baseline indicates that a normoglycemic, normo-insulinemic and/or non-dyslipidemic patient has developed or has an increased likelihood of developing occult pancreatic beta cell dysfunction.

Abstract: This invention relates to a method for detecting the presence of or likelihood of a patient of developing occult pancreatic beta cell dysfunction, and a method for detecting the presence of or likelihood of a patient of developing clinically significant post-prandial hyperglycemia. The methods involve (a) measuring a level of alpha-hydroxybutyrate (AHB) in a single fasting baseline biological sample of the patient; (b) comparing the level of AHB in the single fasting baseline biological sample to a reference AHB level; and (c) determining the presence of or likelihood of developing the disorder in the patient based on the comparison in step (b). An increased AHB level at fasting baseline indicates that a normoglycemic, normo-insulinemic and/or non-dyslipidemic patient has developed or has an increased likelihood of developing occult pancreatic beta cell dysfunction.

Abstract: The present disclosure relates to methods of predicting the likelihood of a subject having impaired glucose tolerance or insulin resistance by measuring a novel set of fasting blood biomarkers.

Abstract: The present invention provides blood based methods for assessing adolescent depression in a subject.

Abstract: The present invention provides blood based methods for predicting risk of acute coronary syndrome in a subject.

Abstract: The present invention provides blood based methods for predicting risk of acute coronary syndrome in a subject.

Abstract: A method for generating a report presenting a patient-specific information relevant to assessing a patient's cardiodiabetes risk to guide and allow a physician or healthcare provider in the choice of therapy or therapies that will be maximally effective for a specific patient, to monitor the response to the chosen therapy and reduce the patient's risk of developing cardiodiabetes and/or its complications.

Abstract: The present invention provides blood based methods for predicting risk of acute coronary syndrome in a subject.

Abstract: The present invention provides blood based methods for predicting risk of acute coronary syndrome in a subject.

Abstract: A single handed squeeze lancet and methods for its use, where the single handed squeeze lancet comprises (a) a lancet, (b) a lancet-holder, (c) an internal housing for receiving and guiding the lancet-holder, (d) an external housing for receiving and guiding the internal housing, (e) a thumb-frame coupled to the external housing, and (f) a thumb-spring coupled to the thumb-frame and coupled to the lancet-holder. The device may further comprise a base-stand coupled to the thumb-frame.

Abstract: The present invention provides blood based methods for assessing adolescent depression in a subject.

Abstract: The present invention provides blood based methods for predicting risk of acute coronary syndrome in a subject.

Abstract: A communication apparatus (100) includes an automatically configured multimode talk switch (154). The communication apparatus (100) can be operated in a simplex communication mode, for receive or transmit operations, and a duplex communication mode, for simultaneous receive and transmit operations. The switch (154) is automatically configured as a push-to-talk momentary switch when the communication apparatus operates in the simplex communication mode (232, 235), and automatically configured as an on-hook/off-hook switch, when the communication apparatus operates in the duplex communication mode (242,245).

Abstract: A self-latching antenna field coupler (120) includes two housing members (210, 230). One of the housing members (230) is movable, relative to the other housing member (210), between a first position to define an antenna receiving channel (222), and a second position to define a secured antenna chamber (322). A latch actuator (250) is mechanically coupled to the movable housing member (230), to automatically effect movement of the movable housing member (230) from the first position to the second position when an antenna (195) is received in the antenna receiving channel (222).